Cell Therapy News/Articles, page-5724

Hi @Huge Jaxxon.

I did reply earlier but for some reason it didn't link to your question (so second attempt).

I also see that @Zenox has replied.

I went and found ecoool2's response to my similar question see below hope it helps.

"You asked a valid question about randomisation.Randomised allocation means participants are assigned to the arms of a clinical trial by chance. Not allocated per hospital or according to any other criteria that could unblind the study – it has to be truly random. This is a double blinded, triple masked trial – so nobody knows where the patients will receive the treatment and where they will receive placebo. It is possible 10 patients in one hospital all receive MSB cells and 10 patients in a hospital on the other side of the country all receive placebo (probably not likely however). That’s why you have a 300 person trial, to diminish the potential of skewed results from a smaller sample.Initially the trial was planned to be 240 patients, then was increased to 300 to provide the FDA with an appropriately “powered” trial."

This explains why it would bloody hard for any person involved in the trial to pre-determine the result.